Regulus Therapeutics Inc. (NASDAQ: RGLS) Starts Presentation at 29th Annual Roth Conference
Regulus Therapeutics (NASDAQ: RGLS) is a biopharmaceutical company that focuses on the discovery and development of drugs that target RNAs to treat a broad range of diseases. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes. For more information, visit the company’s website at www.regulusrx.com.…







